Life Edit Therapeutics
Adrian Pickar Oliver, Ph.D., currently serves as Associate Director of Technology Development and previously as Senior Scientist of Technology Development at Life Edit Therapeutics since May 2021. Prior to this role, Adrian gained experience at Duke University as a Research Scientist and Postdoctoral Fellow from October 2015 to May 2021. Adrian completed PhD work in Dr. Biao He's lab at the University of Georgia, focusing on the phosphorylation of the mumps virus phosphoprotein in viral pathogenesis to develop vaccine candidates. Earlier experience includes a research internship at the US Department of Defense in the Viral Therapeutics Branch and undergraduate research under Dr. Boland at the University of Richmond, studying the effect of arachidonic acid on potassium ion channels. Adrian holds a PhD in Infectious Diseases from the University of Georgia and a BS in Biology and Chemistry from the University of Richmond.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.